Measure ID: MIPS 112·Breast Cancer·2026 Performance Year
2026 MIPS Measure #112: Breast Cancer Screening
Percentage of women 40 - 74 years of age who had a mammogram to screen for breast cancer in the 27 months prior to the end of the measurement period.
Measure Specification
Why This Measure Matters
The CMS 2026 benchmark file labels MIPS Measure 112 "Not available in Traditional MIPS." VBCA is a CMS-approved Qualified Clinical Data Registry (QCDR) and can submit MIPS Measure 112 to the Quality Payment Program (QPP) as a MIPS Clinical Quality Measure (CQM) or an eCQM. CMS lists these 2026 collection types for the measure: MIPS CQM, Medicare Part B Claims, and eCQM.
🧮MIPS Score Simulator
Estimate only — actual CMS scoring may vary based on reporting method, data completeness, and annual rule updates.
No benchmarks available for this measure.
Related Measures
Clinical Context
Clinical Rationale
Breast cancer is one of the most common types of cancers, accounting for 15 percent of all new cancer diagnoses in the U.S.. In 2015, over 3 million women were estimated to be living with breast cancer in the U.S. and it is estimated that 12 percent of women will be diagnosed with breast cancer at some point during their lifetime. While there are other factors that affect a woman's risk of developing breast cancer, advancing age is a primary risk factor.
Breast cancer is most frequently diagnosed among women ages 55-64; the median age at diagnosis is 62 years. The chance of a woman being diagnosed with breast cancer in a given year increases with age. By age 40, the chances are 1 in 68; by age 50 it becomes 1 in 43; by age 60, it is 1 in 29.
Clinical Recommendations
The U.S. Preventive Services Task Force (USPSTF) recommends biennial screening mammography for women aged 40-74 years (B recommendation) (USPSTF, 2024). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening mammography in women aged 75 years or older (I statement) (USPSTF, 2024). The USPSTF concludes that the current evidence is insufficient to assess the benefits and harms of digital breast tomosynthesis (DBT) as a primary screening method for breast cancer (I Statement) (USPSTF, 2024).
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of adjunctive screening for breast cancer using breast ultrasonography, magnetic resonance imaging, in women identified to have dense breasts on an otherwise negative screening mammogram (I statement) (USPSTF, 2024). The National Comprehensive Cancer Network (NCCN) and the American College of Radiology (ACR) recommend using conventional mammography or DBT for screening women at low, intermediate or high risk for breast cancer (NCCN, 2021) (ACR, 2017).
Implementation Notes
This measure contains one strata defined by a single submission criteria. This measure produces a single performance rate. For the purposes of MIPS implementation, this patient-process measure is submitted a minimum of once per patient during the performance period. The most advantageous quality data code (QDC) will be used if the measure is submitted more than once.
This measure specification is only available for MIPS Value Pathway (MVP) reporting and is not available for traditional MIPS reporting.
Frequently Asked Questions
Report this measure through VBCA
Our QCDR handles measure selection, data validation, and submission—so you can focus on clinical performance.
This Physician Performance Measure (Measure) and related data specifications are owned and were developed by the